BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 16202591)

  • 21. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
    Zhao G; Yuan C; Wind T; Huang Z; Andreasen PA; Huang M
    J Struct Biol; 2007 Oct; 160(1):1-10. PubMed ID: 17692534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
    Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
    Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors.
    Zeslawska E; Jacob U; Schweinitz A; Coombs G; Bode W; Madison E
    J Mol Biol; 2003 Apr; 328(1):109-18. PubMed ID: 12684001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines.
    Fish PV; Barber CG; Brown DG; Butt R; Collis MG; Dickinson RP; Henry BT; Horne VA; Huggins JP; King E; O'Gara M; McCleverty D; McIntosh F; Phillips C; Webster R
    J Med Chem; 2007 May; 50(10):2341-51. PubMed ID: 17447747
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
    Bhongade BA; Gouripur VV; Gadad AK
    Bioorg Med Chem; 2005 Apr; 13(8):2773-82. PubMed ID: 15781388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasminogen activator inhibitor-2 is highly tolerant to P8 residue substitution--implications for serpin mechanistic model and prediction of nsSNP activities.
    Di Giusto DA; Sutherland AP; Jankova L; Harrop SJ; Curmi PM; King GC
    J Mol Biol; 2005 Nov; 353(5):1069-80. PubMed ID: 16214170
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position.
    Joossens J; Van der Veken P; Surpateanu G; Lambeir AM; El-Sayed I; Ali OM; Augustyns K; Haemers A
    J Med Chem; 2006 Sep; 49(19):5785-93. PubMed ID: 16970403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Geometry of binding of the N alpha-tosylated piperidides of m-amidino-, p-amidino- and p-guanidino phenylalanine to thrombin and trypsin. X-ray crystal structures of their trypsin complexes and modeling of their thrombin complexes.
    Turk D; Stürzebecher J; Bode W
    FEBS Lett; 1991 Aug; 287(1-2):133-8. PubMed ID: 1879520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.
    Sperl S; Jacob U; Arroyo de Prada N; Stürzebecher J; Wilhelm OG; Bode W; Magdolen V; Huber R; Moroder L
    Proc Natl Acad Sci U S A; 2000 May; 97(10):5113-8. PubMed ID: 10805774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthetic urokinase inhibitors as potential antitumor drugs.
    Steinmetzer T
    IDrugs; 2003 Feb; 6(2):138-46. PubMed ID: 12789617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.
    Kromann-Hansen T; Louise Lange E; Peter Sørensen H; Hassanzadeh-Ghassabeh G; Huang M; Jensen JK; Muyldermans S; Declerck PJ; Komives EA; Andreasen PA
    Sci Rep; 2017 Jun; 7(1):3385. PubMed ID: 28611361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.
    Katz BA; Elrod K; Verner E; Mackman RL; Luong C; Shrader WD; Sendzik M; Spencer JR; Sprengeler PA; Kolesnikov A; Tai VW; Hui HC; Breitenbucher JG; Allen D; Janc JW
    J Mol Biol; 2003 May; 329(1):93-120. PubMed ID: 12742021
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.
    Nozaki S; Endo Y; Nakahara H; Yoshizawa K; Ohara T; Yamamoto E
    Anticancer Drugs; 2006 Nov; 17(10):1109-17. PubMed ID: 17075310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is inhibition process better described with MD(QM/MM) simulations? The case of urokinase type plasminogen activator inhibitors.
    Barbault F; Maurel F
    J Comput Chem; 2012 Mar; 33(6):607-16. PubMed ID: 22241532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
    Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
    J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
    Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
    Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.
    Mackman RL; Hui HC; Breitenbucher JG; Katz BA; Luong C; Martelli A; McGee D; Radika K; Sendzik M; Spencer JR; Sprengeler PA; Tario J; Verner E; Wang J
    Bioorg Med Chem Lett; 2002 Aug; 12(15):2019-22. PubMed ID: 12113832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
    Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
    J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.